ClinConnect ClinConnect Logo
Search / Trial NCT01906151

IOP Pattern in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After LPI

Launched by SENSIMED AG · Jul 19, 2013

Trial Information

Current as of April 29, 2025

Withdrawn

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Diagnosis of Primary Angle Closure (PAC) or Primary Angle Closure Glaucoma (PACG) with indication for Laser Peripheral Iridotomy (LPI). PAC is defined by the presence of a partial or complete iridotrabecular contact(ITC) in more than 2 quadrants with either raised intraocular pressure (IOP) (ie. more than 21 mmHg) and/or PAS; however, with normal optic disc and visual field. PACG is defined by the presence of ITC with either raised IOP and/or PAS, and evidence of glaucomatous optic disc and visual field
  • No IOP-lowering drug treatment or a 4-week wash-out period prior to Study Day 0
  • Aged ≥18 years, of either sex
  • Not more than 6 diopters spherical equivalent on the study eye
  • Have given written informed consent, prior to any investigational procedures
  • Exclusion Criteria:
  • History of acute angle closure glaucoma on the study eye
  • Secondary angle closure glaucoma on the study eye
  • History of ocular surgery within the last 3 months on the study eye
  • History of ocular laser treatment, including previous LPI on the study eye
  • Corneal or conjunctival abnormality precluding contact lens adaptation on the study eye
  • Severe dry eye syndrome on the study eye
  • Patients with allergy to corneal anesthetic
  • Patients with contraindications for silicone contact lens wear
  • Patients not able to understand the character and individual consequences of the investigation

About Sensimed Ag

Sensimed AG is a pioneering medical technology company specializing in the development of innovative solutions for the management of ocular diseases, particularly glaucoma. Headquartered in Switzerland, Sensimed is renowned for its cutting-edge wearable sensor technology that enables continuous monitoring of intraocular pressure, providing valuable insights for both patients and healthcare providers. The company's commitment to advancing eye care through research and clinical trials underscores its dedication to improving patient outcomes and enhancing the understanding of chronic eye conditions. With a strong emphasis on collaboration and innovation, Sensimed AG is at the forefront of transforming the landscape of ophthalmic diagnostics and treatment.

Locations

Paris, , France

Patients applied

0 patients applied

Trial Officials

Christophe Baudouin, MD

Principal Investigator

CHNO des Quinze-Vingts, 28 rue Charenton, 75571 Paris Cedex 12, France

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials